ライフサイエンスコーパス: carmustine

1 emotherapy (cyclophosphamide, cisplatin, and carmustine).

2 godendrogliomas treated with temozolomide or carmustine.

3 doxorubicin, dactinomycin, dacarbazine, and carmustine.

4 y high-dose cyclophosphamide, cisplatin, and carmustine.

5 agents such as procarbazine, lomustine, and carmustine.

6 High drug concentrations (0.5-3.5 mM for carmustine, 0.3-0.4 mM for 4-HC, and 0.2-1.0 mM for pacl

7 animals and 26 days in animals treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea 20 mg/k

8 ined from patients who had been treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCN

9 , mitoxantrone, chlorambucil, melphalan, and carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)]

10 The failure of alkylating agents, such as carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea; BCNU],

11 g/m(2) and cisplatin 25 mg/m(2) days 1 to 3, carmustine 150 mg/m(2) day 1 every other cycle, and tamo

12 ) on days 1 through 3 and 22 through 24 plus carmustine (150 mg/m2) on day 1.

13 polymer implant; significant (0.4 microM for carmustine, 3 microM for 4-HC, and 0.6 microM for paclit

14 and therapeutic dose of 0.75 Gy on day -12), carmustine 300 mg/m(2) (day -6), etoposide 100 mg/m(2) t

15 Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) o

16 Either [3H]carmustine, 4-hydroperoxycyclophosphamide (4-HC), or pac

17 ous HCT-ASCT (rituximab 375 mg/m(2) [day 1], carmustine 400 mg/m(2) [day 2], thiotepa 2 x 5 mg/kg [da

18 D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/m(2) on day -6, and thiotepa 5 mg/kg e

19 us gene-modified HSCs following single-agent carmustine administration.

20 fractionation total lymphoid irradiation or carmustine and ASCT.

21 phamide and either total body irradiation or carmustine and autografting (median follow-up, 3.6 years

22 th the alkylating agents temozolomide (TMZ), carmustine and chlorambucil.

23 Topical carmustine and intravenous O6-benzylguanine.

24 anine (O(6)BG) and nitrosourea drugs such as carmustine and methylating agents such as temozolomide.

25 onses and 8 partial responses to combination carmustine and O6-benzylguanine treatment.

26 num treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) plus autologous hematopo

27 n most frequently used was cyclophosphamide, carmustine, and etoposide (n = 47).

28 e Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor respon

29 ne O(6)-targeting drugs such as cloretazine, carmustine, and temozolomide and that (ii) AGT levels in

30 The MTD was 20 mg of carmustine applied once in combination with 2 daily dose

31 c analysis indicated that tissue exposure to carmustine area under concentration-time curve achieved

32 tiforme, to determine whether cisplatin plus carmustine (BCNU) administered before and concurrently w

33 ain tumors was correlated with resistance to carmustine (BCNU) chemotherapy.

34 tivity of the combination of thalidomide and carmustine (BCNU) in patients with recurrent high-grade

35 We conducted a phase I trial of carmustine (BCNU) plus O(6)-BG to define the toxicity an

36 We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltr

37 of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the progressio

38 etermine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable

39 Local delivery of carmustine (BCNU) via biodegradable polymers prolongs su

40 h high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) with AHPCS.

41 d high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) with PBPC support.

42 entiated cells exposed to sublethal doses of carmustine (BCNU), a classic alkylating chemotherapeutic

43 adiation (TBI) (67 patients) or an augmented carmustine (BCNU), cyclophosphamide, and etoposide (BCV)

44 The combination of carmustine (BCNU), dacarbazine (DTIC), cisplatin (DDP),

45 d in 81 patients following chemotherapy with carmustine (BCNU), etoposide, cytarabine, and melphalan

46 form O(6)-alkylguanine DNA adducts, such as carmustine (BCNU), temozolomide, streptozotocin, and dac

47 rease in the LD(50) for DNA-alkylating agent carmustine (BCNU), which is commonly used to treat gliom

48 regimen was cyclophosphamide (6,000 mg/m2), carmustine (BCNU; 450 mg/m2), and thiotepa (720 mg/m2) (

49 three patients), or thiotepa, etoposide, and carmustine (BCNU; one patient).

50 in those patients treated with chemotherapy [carmustine [BCNU], vincristine, flourouracil, and strept

51 determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly be

52 atumoural transport, including fluorouracil, carmustine, cisplatin, methotrexate, doxorubicin and pac

53 90 (90Y) ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (BEAM)

54 tuximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemoth

55 her overall response rates and reduced total carmustine doses but was associated with more cutaneous

56 mpared with single-dose O6-benzylguanine and carmustine, dual-dose O6-benzylguanine resulted in highe

57 (5-FU) or 5-FU + leucovorin, doxorubicin, or carmustine] enhance the antitumor effects, compared to 1

58 disease in patients who underwent high-dose carmustine, etoposide, and cyclophosphamide chemotherapy

59 Patients then received high doses of carmustine, etoposide, and cyclophosphamide followed by

60 All patients received carmustine, etoposide, cytarabine, and cyclophosphamide

61 rastim-mobilized PBPCT versus ABMT following carmustine, etoposide, cytarabine, and melphalan (BEAM)

62 Patients were prepared using carmustine, etoposide, cytarabine, and melphalan and rec

63 pants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well

64 maging then received high-dose therapy using carmustine, etoposide, cytarabine, and melphalan with au

65 ntation using BEAM-alemtuzumab conditioning (carmustine, etoposide, cytosine arabinoside, melphalan,

66 l, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA throu

67 r high-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) with stem-cell support or intermedia

68 ediate-dose cyclophosphamide, cisplatin, and carmustine (ID-CPB) with G-CSF support but without stem

69 To determine whether dose escalation of carmustine in combination with dual-dose O6-benzylguanin

70 splatin-, nitrogen mustard-, mitomycin-, and carmustine-induced DNA adducts in S. cerevisiae are proc

71 s with prior radiotherapy received 450 mg/m2 carmustine instead of TBI.

72 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, Carmustine) into biodegradable polymer poly(lactic-co-gl

73 HCT-ASCT with thiotepa and carmustine is an effective treatment option in young pat

74 and prednisone (52 patients) or vincristine, carmustine, melphalan, cyclophosphamide, and prednisone

75 he response criteria: 15 in the vincristine, carmustine, melphalan, cyclophosphamide, and prednisone

76 EM trials: GEM2000 [VBMCP/VBAD (vincristine, carmustine, melphalan, cyclophosphamide, prednisone/vinc

77 status (P =.03), and cisplatin, carboplatin, carmustine or lomustine administration (P =.0002).

78 MF type, to evaluate treatment using topical carmustine plus 2 subsequent daily doses of intravenous

79 elapse-related mortality was increased after carmustine (RR = 2.3) and with use of peripheral blood s

80 gimen, with cyclophosphamide, cisplatin, and carmustine (STAMP-I), followed by autologous stem-cell t

81 years and were naive to prior use of topical carmustine therapy.

82 from the last induction course; group D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/

83 Nitrosoureas of the carmustine type inhibit only the NADPH reduced form of h

84 Additionally, i.c. delivery of carmustine via biodegradable polymers has been shown to

85 e optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics

86 coadministered with intracranially implanted carmustine wafers, without added toxicity.

87 r 14 days after surgical implantation of the carmustine wafers.

88 The MTD for dual-dose O6-benzylguanine plus carmustine was also ascertained.

89 to receive HDC (cyclophosphamide, cisplatin, carmustine), with autologous bone marrow rescue immediat